The CEPI centralised laboratory network: supporting COVID-19 vaccine development

With a wide range of COVID-19 vaccine development platforms and extensive variability between laboratory assays, comparison of results for vaccine trials can be challenging.1 The Coalition for Epidemic Preparedness Innovations (CEPI) has established a global network of laboratories to centralise tes...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2021-06, Vol.397 (10290), p.2148-2149
Main Authors: Kumar, Arun, Bernasconi, Valentina, Manak, Mark, de Almeida Aranha, Ana Paula, Kristiansen, Paul A
Format: Article
Language:English
Subjects:
Antibodies
Cell-mediated immunity
Coronaviruses
Correspondence
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - supply & distribution
Enzyme-linked immunosorbent assay
Geographical locations
Humans
Immunogenicity, Vaccine
Immunology
Interferon
Interleukin 5
Internationality
Laboratories
Laboratories - standards
Peptides
Public health
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccine development
Vaccines
Viral diseases
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With a wide range of COVID-19 vaccine development platforms and extensive variability between laboratory assays, comparison of results for vaccine trials can be challenging.1 The Coalition for Epidemic Preparedness Innovations (CEPI) has established a global network of laboratories to centralise testing and enable comparison of immunological responses generated by COVID-19 vaccines. The laboratories currently included in the CEPI centralised laboratory network2–4 are Nexelis, Public Health England, VisMederi, Viroclinics–DDL, International Centre for Diarrhoeal Disease Research Bangladesh, Translational Health Sciences and Technological Institute, UK National Institute for Biological Standards and Control, Q2 Solutions, and Universidad Nacional Autónoma de México (for geographical locations see appendix). Cell-mediated immunity is measured by the enzyme-linked immunospot (ELISpot) assay, which detects production of interferon-γ and interleukin-5 to SARS-CoV-2 spike protein peptides.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(21)00982-X